Clinical trials: Unresectable Biliary Tract Cancer
Cholangiocarcinoma Non-resectable
Cadonilimab With Chemotherapy in Treating Advanced Biliary Cancer
The goal of this single-arm, Phase II interventional clinical trial is to test the safety and effectiveness of a combination treatment using the Cadonilimab with Gemcitabine and Cisplatin in patients with unresectable, locally…
- Trial name
- NCT05978609
- Testing
- Candonilimab, Cisplatin, Gemcitabine
- Where
- China
- Volunteers
- 65 people
- Sponsor
- West China Hospital
Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells.
- Conditions
- Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer, Bone Metastases, Carcinoma of the Appendix
- Trial name
- NCT00004074
- Testing
- recombinant interleukin-12, ABI-007/carboplatin/trastuzumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Advanced or Metastatic Biliary Tract Cancer
A Study of MRG003 in the Treatment of EGFR-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer
The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG003 as single agent in EGFR-positive unresectable locally advanced or metastatic biliary tract cancer patients who have…
- Trial name
- NCT04838964
- Testing
- MRG003
- Where
- 7 sites in China
- Volunteers
- 15 people
- Sponsor
- Lepu Biopharma Co., Ltd.
Biliary Tract Cancer
Hepatic Arterial Infusion Chemotherapy Plus Envafolimab and Lenvatinib for First-Line Unresectable Advanced Biliary Tract Cancer
Advanced biliary tract cancer has a poor prognosis and limited efficacy with current regimens. This multicenter single-arm phase Ib/II trial explores the efficacy and safety of HAI-GP chemotherapy combined with intraoperative…
- Trial name
- NCT07636798
- Testing
- HAIC Combined Regimen Treatment Group
- Where
- China
- Volunteers
- 20 people
- Sponsor
- West China Hospital
Hilar Cholangiocarcinoma
Treatment of Non-resectable Bile Duct Cancer with Radiofrequency Ablation or Photodynamic Therapy
Bile duct cancer is often diagnosed after curative options are no longer available. Stent therapy is used to keep the ducts open and can be combined with photodynamic therapy (PDT) to extend life expectancy.
- Trial name
- CARP (NCT05551299)
- Testing
- Photosensitizer, Radiofrequency ablation (RFA)
- Where
- 20 sites in Germany
- Volunteers
- 258 people
- Sponsor
- University of Leipzig
Cholangiocarcinoma
Gemcitabine + Oxaliplatin +Nab-paclitaxel in Subjects With Advanced Biliary Tract Cancer
The objective of the study is to determine a new combination of drug that improves the outcome in patients with advanced (unresectable or metastatic) BTC.
- Trial name
- NCT03943043
- Testing
- nab-paclitaxel
- Where
- Italy
- Volunteers
- 85 people
- Sponsor
- Istituto Clinico Humanitas
Biliary Tract Cancer, Gallbladder Adenocarcinoma
Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer
The main purpose of this study is to test the safety and effectiveness of oxaliplatin, bevacizumab, and capecitabine given in combination with radiation therapy to see what effects (good or bad) they have on patients with biliary…
- Trial name
- NCT00142480
- Testing
- Capecitabine, Oxaliplatin, Bevacizumab
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- Massachusetts General Hospital
Cholangiocarcinoma, Hepatobiliary Neoplasm
Phase II SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver Transplantation
The purpose of this study is to determine progression-free survival at 12 months for stereotactic body radiotherapy (SBRT) and chemotherapy for unresectable hilar cholangiocarcinoma (CCA).
- Conditions
- Cholangiocarcinoma, Hepatobiliary Neoplasm, Liver Cancer, Bile Duct Cancer
- Trial name
- NCT01151761
- Testing
- Stereotactic Body Radiotherapy, Gemcitabine, Cisplatin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Stanford University
Gallbladder Cancer
Palliative Biliary Stenting on the Quality of Life of Patients With Unresectable Carcinoma Gallbladder With Hiliar Block.
The purpose of the study is to determine whether palliative biliary stenting improves the quality of life, of gallblader cancer patients, who present with hilar block and obstructive jaundice.
- Trial name
- NCT00391183
- Testing
- Biliary stenting
- Where
- India
- Volunteers
- 60 people
- Sponsor
- All India Institute of Medical Sciences
Adenocarcinoma of the Extrahepatic Bile Duct, Adenocarcinoma of the Gallbladder
Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder
This phase II trial is studying how well bortezomib works as first-line systemic therapy in treating patients with unresectable locally advanced or metastatic adenocarcinoma (cancer) of the bile duct or gallbladder.
- Conditions
- Adenocarcinoma of the Extrahepatic Bile Duct, Adenocarcinoma of the Gallbladder, Advanced Adult Primary Liver Cancer, Gastrointestinal Cancer
- Trial name
- NCT00085410
- Testing
- bortezomib
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Biliary Tract Cancer
Study of PD-1 Inhibitor in Combination With Gemcitabine/Cisplatin for Advancer BTCs
This is a single-arm, phase I/II trial in biliary tract cancer (BTC) patients. The purpose of this trial is to evaluate the safety and effect of PD-1 inhibitor in combination with gemcitabine/cisplatin chemotherapy in patients…
- Trial name
- NCT03311789
- Testing
- PD-1 inhibitor + Gemcitabine + Cisplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
Unresectable Biliary Tract Cancer
Salvage mFOLFOX in BTC After Failure of Gemcitabine
The purpose of this study is to evaluate the efficacy and safety of mFOLFOX (5-fluorouracil, leucovorin, oxaliplatin)as salvage therapy in patients with unresectable biliary tract cancer who had failed gemcitabine.
- Trial name
- NCT01127555
- Testing
- 5-fluorouracil, leucovorin, oxaliplatin
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Chung-Ang University
Biliary Tract Neoplasms, Cholangiocarcinoma
ABC-04 a Study of Cisplatin, Gemcitabine and Selumetinib in Patients With Advanced Biliary Tract Cancer
The objective of this study is to establish the recommended dose of selumetinib, a novel MEK inhibitor for use in combination with gemcitabine and cisplatin.
- Conditions
- Biliary Tract Neoplasms, Cholangiocarcinoma, Gallbladder Neoplasms
- Trial name
- ABC-04 (NCT01242605)
- Testing
- selumetinib, gemcitabine, cisplatin
- Where
- 3 sites in United Kingdom
- Volunteers
- 13 people
- Sponsor
- University College, London
Stomach Cancer, Gall Bladder Cancer
Study of Capecitabine and Oxaliplatin in Combination With Radiotherapy in Patients With Unresectable Gastro-Intestinal Cancer
The purpose with this study is to evaluate treatment with radio chemotherapy (oxaliplatin and capecitabine) given concommitant with radiotherapy in patients with gastrointestinal tumors.
- Conditions
- Stomach Cancer, Gall Bladder Cancer, Bile Ductus Cancer, Pancreas Cancer
- Trial name
- CORGI (NCT01016639)
- Testing
- oxaliplatin, capecitabine, radiotherapy
- Where
- 5 sites in Sweden
- Volunteers
- 106 people
- Sponsor
- Lund University Hospital
Biliary Tract Cancer
Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
The purpose of this research study is to determine the safety and efficacy of CPI-613 (devimistat) in the treatment of advanced biliary tract cancer when used in combination with standard of care chemotherapy (gemcitabine plus…
- Trial name
- NCT04203160
- Testing
- CPI 613, Gemcitabine, Cisplatin
- Where
- 10 sites in United States
- Volunteers
- 75 people
- Sponsor
- University of Michigan Rogel Cancer Center
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Gemcitabine With or Without Cisplatin in Treating Patients With Unresectable Locally Advanced or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- ABC-02 (NCT00262769)
- Testing
- cisplatin, gemcitabine hydrochloride
- Where
- 25 sites in United Kingdom
- Volunteers
- 324 people
- Sponsor
- University College, London
Biliary Tract Cancer
Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cancer
This prospective real-world study aims to evaluate the effectiveness and safety of an alternating treatment regimen combining hepatic arterial infusion chemotherapy (HAIC) with systemic chemotherapy, with or without adebrelimab…
- Trial name
- NCT07569679
- Testing
- HAIC, Gemcitabine plus Cisplatin, Adebrelimab
- Where
- China
- Volunteers
- 124 people
- Sponsor
- Air Force Military Medical University, China
Biliary Tract Cancer
Consolidative Radiotherapy (CSRT) in Patients With Oligometastatic/Locally Advanced Unresectable Bilary Tract Cancer (BTC)
The purpose of this clinical trial is to investigate whether the inclusion of radiotherapy, in addition to standard-of-care systemic therapy, could improve the treatment effectiveness of patients with oligometastatic/locally…
- Trial name
- RADITOP (NCT06502080)
- Testing
- Consolidative radiotherapy, Standard-of-care systemic therapy: Gemcitabine + cisplatin/oxaliplatin + Durvalumab/Pembrolizumab/Sintilimab/Toripalimab
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Shanghai Zhongshan Hospital